Novel cAMP binding protein-BP (CREBBP) mutation in a girl with Rubinstein-Taybi syndrome, GH deficiency, Arnold Chiari malformation and pituitary hypoplasia.
Pierluigi Marzuillo, Anna Grandone, Ruggero Coppola, Domenico Cozzolino, Adalgisa Festa, Federica Messa, Caterina Luongo, Emanuele Miraglia Del Giudice, Laura Perrone
Index: BMC Med. Genet. 14 , 28, (2013)
Full Text: HTML
Abstract
Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder (prevalence 1:125,000) characterised by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects, abnormalities in the posterior fossa and short stature. The known genetic causes are point mutations or deletions of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) (5%).We describe, for the first time in literature, a RTS Caucasian girl, 14-year-old, with growth hormone (GH) deficiency, pituitary hypoplasia, Arnold Chiari malformation type 1, double syringomyelic cavity and a novel CREBBP mutation (c.3546insCC).We hypothesize that CREBBP mutation we have identified in this patient could be responsible also for RTS atypical features as GH deficiency and pituitary hypoplasia.
Related Compounds
Related Articles:
2014-12-03
[J. Neurosci. 34(49) , 16309-19, (2014)]
2015-01-01
[Endocrinology 156(1) , 193-202, (2015)]
2014-07-25
[Life Sci. 109(1) , 20-9, (2014)]
GH administration patterns differently regulate epidermal growth factor signaling.
2014-05-01
[J. Endocrinol. 221(2) , 317-23, (2014)]
Supplement use by UK-based British Army soldiers in training.
2014-10-14
[Br. J. Nutr. 112(7) , 1175-84, (2014)]